UPDATE 4-AstraZeneca hit by double Pulmicort, Zactima blow

* Mixed results in late-stage Zactima trial

* Announces deal with Par over Pulmicort generic

* Says deal follows launch by rival Teva of generic

* Predicts full-year EPS at low end of range after deal

* Shares off 11 percent with FTSE 100 down 1.7 pct

(Adds FY EPS predictions, Par deal)

By Ben Deighton

LONDON, Nov 19 (Reuters) - Anglo-Swedish drugmaker AstraZeneca (AZN.L) saw shares plummet 11 percent on Wednesday after it said its full-year earnings per share (EPS) would be at the lower end of its previously stated range.

Earnings would be hit by about $0.16 per share after it signed a distribution and supply deal with Par Pharmaceutical (PRX.N) for an authorised generic of its asthma drug Pulmicort.